Daan Gene's (SHE:002030) unit, Guangzhou Darui Biotechnology, obtained a medical device registration certificate from the Chinese drug administration for an assay kit detecting syphilis treponema, according to a Shenzhen Stock Exchange filing on Thursday.
The certificate, valid until Feb. 10, 2030, is for the syphilis treponema antibody detection kit (chemiluminescent immunoassay), the Chinese medical laboratory company said.
The company's shares soared 10% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.